Name: 글로벌 시장 동향
SKU: PH2105
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 카르시노이드 증후군 설사 치료 시장은 2022년 35억 1,430만 달러에 달했으며, 2030년까지 72억 7,560만 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 전 세계 카르시노이드 증후군 설사 치료 시장은 예측 기간(2023-2030년) 동안 연평균 9.8%의 성장률을 기록할 것으로 전망됩니다.
카르시노이드 증후군 설사는 증상 조절 및 삶의 질 향상을 위해 지속적인 관리와 치료가 필요한 만성 질환입니다. 치료 목표는 설사를 조절하고 세로토닌 생성 및 그 영향, 그리고 기타 관련 증상을 최소화하는 것입니다. 이를 위해 텔로트리스타트 에틸 및 소마토스타틴 유사체와 같은 약물 사용과 보조 치료가 병행될 수 있습니다.
시장 동향
치료 옵션의 발전이 전 세계 카르시노이드 증후군 설사 치료 시장 성장을 촉진하고 있습니다.

지속적인 연구와 임상 시험을 통해 카르시노이드 증후군 설사(CSD) 및 신경내분비 종양에 대한 새로운 통찰력이 밝혀짐에 따라 치료 옵션은 계속해서 발전하고 있습니다. 표적 치료법 개발과 카르시노이드 증후군 설사에 대한 개선된 치료법은 시장 성장을 견인해 왔습니다. 예를 들어, 소마토스타틴 유사체인 텔로트리스타트 에틸 및 기타 신약의 도입은 환자들에게 더욱 효과적인 증상 조절 및 관리를 제공했습니다.
향상된 진단 기술은 전 세계 카르시노이드 증후군 설사 치료 시장에 유망한 성장 기회를 제공하고 있습니다.
진단 기술의 개발 및 개선은 카르시노이드 증후군 설사의 진단 증가에 기여했습니다. 소변 내 5-하이드록시인돌아세트산(5-HIAA) 수치 측정과 같은 바이오마커 검사는 카르시노이드 증후군 설사와 관련된 신경내분비 종양의 존재를 확인하는 데 중요한 역할을 합니다. 컴퓨터 단층 촬영(CT) 스캔 및 소마토스타틴 수용체 영상과 같은 첨단 영상 기술은 종양의 위치 파악 및 평가에 도움이 됩니다.

COVID-19 영향 분석
COVID-19 팬데믹은 카르시노이드 증후군 설사 치료 시장에 상당한 영향을 미쳤습니다. 많은 의료 전문가들이 바이러스 전파 위험을 줄이고 서비스 연속성을 보장하기 위해 원격 진료 및 원격 치료 솔루션으로 전환했습니다. 의료 전문가들은 화상 상담 및 원격 의료 기술 덕분에 카르시노이드 증후군 설사 환자를 원격으로 진찰하고, 조언을 제공하며, 필요에 따라 치료 프로그램을 조정할 수 있었습니다. 팬데믹으로 인해 대면 수술이나 전문 검사와 같은 카르시노이드 증후군 설사 관리의 일부 측면이 지연되거나 제한되었을 수 있지만, 원격 진료는 지속적인 치료를 제공하는 데 도움이 되었습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁이 카르시노이드 증후군 설사 치료 시장에 미치는 영향은 복잡하고 다면적입니다. 병원, 진료소, 의료 장비 공급망 모두 분쟁의 영향을 받을 수 있습니다. 이러한 혼란은 카르시노이드 증후군 설사 치료의 접근성과 효능에 영향을 미쳐 환자들이 필요한 약물과 의료 서비스를 받는 것을 더욱 어렵게 만들 수 있습니다.

시장 세분화 분석
전 세계 카르시노이드 증후군 설사 치료 시장은 치료 유형, 유통 채널, 최종 사용자 및 지역별로 세분화됩니다.
소마토스타틴 유사체(SSA) 치료 부문은 예측 기간 동안 시장에서 지배적인 위치를 차지할 것으로 예상됩니다.
소마토스타틴 유사체(SSA) 치료 부문은 2022년 카르시노이드 증후군 설사 치료 시장에서 약 54.04%의 가장 높은 시장 점유율을 차지했습니다. 예를 들어, 2022년 4월 Ipsen은 SERB에 미국과 일본을 제외한 유럽 및 기타 국가에서 Xermelo(텔로트리스타트 에틸)를 판매할 수 있는 라이선스를 부여했습니다. Xermelo는 소마토스타틴 유사체 치료와 병용 시 SSA 약물로 잘 조절되지 않는 성인 카르시노이드 증후군 설사 치료에 승인되었습니다.
지역 분석
카르시노이드 증후군 설사 치료의 기술 발전 및 개선이 북미 지역을 주도하고 있습니다.

북미는 예측 기간 동안 전체 시장 점유율의 약 41.2%를 차지할 것으로 예상됩니다. 북미는 의료 기술 발전의 최전선에 있습니다. 이 지역은 최첨단 진단 도구, 영상 기술 및 실험실 시설을 보유하고 있어 카르시노이드 증후군 설사의 정확한 진단 및 모니터링이 가능합니다. 이러한 발전은 치료 계획 수립 및 치료 결과 평가에 도움이 됩니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Novartis AG, Lexicon Pharmaceuticals, Ipsen Biopharmaceuticals, Pfizer Inc., Hutchison China MediTech Limited (Chi-Med), Progenics Pharmaceuticals, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., Helsinn Group, Omega Laboratories Ltd. 등이 있습니다.
보고서 구매 이유

• 치료 유형, 유통 채널, 최종 사용자 및 지역별 글로벌 카르시노이드 증후군 설사 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 카르시노이드 증후군 설사 치료 시장의 모든 부문에 대한 다양한 데이터가 담긴 엑셀 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 포함된 PDF 보고서

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공

글로벌 카르시노이드 증후군 설사 치료 시장 보고서는 약 61개의 표, 57개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Carcinoid Syndrome Diarrhea Treatment Market reached US$ 3,514.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 7,275.6 million by 2030. The global carcinoid syndrome diarrhea treatment market is expected to exhibit a CAGR of 9.8% during the forecast period (2023-2030).
Carcinoid syndrome diarrhea is a chronic condition that requires ongoing management and treatment to control symptoms and improve the quality of life for affected individuals. The goal of treatment is to regulate diarrhea, and minimize serotonin production and its effects, as well as other related symptoms. This may involve the use of drugs such as telotristat ethyl and somatostatin analogs as well as supportive care techniques.
Market Dynamics
Advancements in Treatment Options Are Boosting The Global Carcinoid Syndrome Diarrhea Treatment Market Growth.
Advancements in treatment options continue to evolve as ongoing research and clinical trials uncover new insights into CSD and neuroendocrine tumors. The development of targeted therapies and improved treatment options for carcinoid syndrome diarrhea has driven the market. For instance, the introduction of somatostatin analogs, telotristat ethyl, and other novel medications has provided more effective symptom control and management for patients.
Improved Diagnostic Techniques Are Providing The Global Carcinoid Syndrome Diarrhea Treatment Market With Prospective Growth Opportunities.
The development and refinement of diagnostic techniques have contributed to the increased diagnosis of noid syndrome diarrhea. Biomarker testing, such as measuring urinary 5-hydroxy indole acetic acid (5-HIAA) levels, plays a crucial role in identifying the presence of neuroendocrine tumors associated with noid syndrome diarrhea. Advanced imaging techniques, such as computed tomography scans and somatostatin receptor imaging, aid in the localization and assessment of tumors.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the carcinoid syndrome diarrhea treatment market. Several medical professionals switched to telemedicine and remote care solutions to reduce the danger of virus transmission and guarantee continuity of service. Healthcare specialists were able to examine carcinoid syndrome diarrhea patients remotely, offer advice, and modify treatment programs as necessary due to virtual consultations and telehealth technologies. The pandemic may have delayed or restricted some aspects of carcinoid syndrome diarrhea management, such as in-person operations or specialized testing, even while telemedicine made it easier to provide continuous care.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the carcinoid syndrome diarrhea treatment market is complex and multifaceted. Hospitals, clinics, and supply networks for medical equipment might all be affected by the conflict. This disturbance may have an impact on the accessibility and efficacy of carcinoid syndrome diarrhea therapies, making it more difficult for patients to obtain the required drugs and medical care.
Segment Analysis
The global carcinoid syndrome diarrhea treatment market is segmented based on therapy type, distribution channel, end-user, and region.
The Somatostatin Analog (SSA) Therapy Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.
The somatostatin analog (SSA) therapy segment accounted for the highest market share accounting for around 54.04% of the carcinoid syndrome diarrhea treatment market in 2022. For instance, in April 2022, Ipsen granted SERB the license to market Xermelo (telotristat ethyl) in Europe and other nations besides the US and Japan. When combined with somatostatin analog therapy, Xermelo is approved for the treatment of adults with carcinoid syndrome diarrhea that is not well controlled by SSA medication.
Geographical Analysis
Technological Advancements And Improvements In Carcinoid Syndrome Diarrhea Treatment Dominate the North American Region.
North America is expected to hold around 41.2% of the total market share throughout the forecast period. North America is at the forefront of technological advancements in healthcare. The region has access to state-of-the-art diagnostic tools, imaging techniques, and laboratory facilities, enabling accurate diagnosis and monitoring of carcinoid syndrome diarrhea. These advancements aid in treatment planning and assessment of treatment outcomes.
Competitive Landscape
The major global players in the market include Novartis AG, Lexicon Pharmaceuticals, Ipsen Biopharmaceuticals, Pfizer Inc., Hutchison China MediTech Limited (Chi-Med), Progenics Pharmaceuticals, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., Helsinn Group, and Omega Laboratories Ltd. among others.
Why Purchase the Report?
• To visualize the global carcinoid syndrome diarrhea treatment market segmentation based on the therapy type, distribution channel, end-user, and region, and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of carcinoid syndrome diarrhea treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global carcinoid syndrome diarrhea treatment market report would provide approximately 61 tables, 57 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by Distribution Channel
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The promising carcinoid syndrome diarrhea pipeline is driving the global carcinoid syndrome diarrhea treatment market growth.
4.1.2. Restraints
4.1.2.1. Lack of is hampering the growth of the global Carcinoid Syndrome Diarrhea Treatment market.
4.1.3. Opportunity
4.1.4. Increasing awareness about carcinoid syndrome diarrhea among patients,
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Therapy Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.1.2. Market Attractiveness Index, By Therapy Type
9.2. Chemotherapy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Somatostatin Analog (SSA) Therapy
9.4. Others
10. By Distribution Channel
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Retail Pharmacy*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospital Pharmacy
10.4. Online Pharmacy
11. By End User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Cancer Research Center
11.4. Ambulatory Surgery Centers
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. The U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. The U.K.
12.3.6.3. France
12.3.6.4. Italy
12.3.6.5. Spain
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. Australia
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. Novartis AG*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Lexicon Pharmaceuticals
14.3. Ipsen Biopharmaceuticals
14.4. Pfizer Inc.
14.5. Hutchison China MediTech Limited (Chi-Med)
14.6. Progenics Pharmaceuticals
14.7. Ipsen Pharma
14.8. Teva Pharmaceutical Industries Ltd.
14.9. Helsinn Group
14.10. Omega Laboratories Ltd.
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Novartis AG, 4.	Key Developments, Lexicon Pharmaceuticals, Ipsen Biopharmaceuticals, Pfizer Inc., Hutchison China MediTech Limited (Chi-Med), Progenics Pharmaceuticals, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., Helsinn Group, Omega Laboratories Ltd.

표 목록 (Tables)

List of Tables

Table 1 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By Therapy Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By Therapy Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 7 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 9 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 11 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Carcinoid Syndrome Diarrhea Treatment Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Carcinoid Syndrome Diarrhea Treatment Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 14 North America Carcinoid Syndrome Diarrhea Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 15 North America Carcinoid Syndrome Diarrhea Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 16 North America Carcinoid Syndrome Diarrhea Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Carcinoid Syndrome Diarrhea Treatment Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 18 South America Carcinoid Syndrome Diarrhea Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 19 South America Carcinoid Syndrome Diarrhea Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 20 South America Carcinoid Syndrome Diarrhea Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Carcinoid Syndrome Diarrhea Treatment Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 22 Europe Carcinoid Syndrome Diarrhea Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 23 Europe Carcinoid Syndrome Diarrhea Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 24 Europe Carcinoid Syndrome Diarrhea Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Carcinoid Syndrome Diarrhea Treatment Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Carcinoid Syndrome Diarrhea Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Carcinoid Syndrome Diarrhea Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 32 Novartis AG: Overview

Table 33 Novartis AG: Product Portfolio

Table 34 Novartis AG: Key Developments

Table 35 Lexicon Pharmaceuticals: Overview

Table 36 Lexicon Pharmaceuticals: Product Portfolio

Table 37 Lexicon Pharmaceuticals: Key Developments

Table 38 Ipsen Biopharmaceuticals: Overview

Table 39 Ipsen Biopharmaceuticals: Product Portfolio

Table 40 Ipsen Biopharmaceuticals: Key Developments

Table 41 Pfizer Inc.: Overview

Table 42 Pfizer Inc.: Product Portfolio

Table 43 Pfizer Inc.: Key Developments

Table 44 Hutchison China MediTech Limited (Chi-Med): Overview

Table 45 Hutchison China MediTech Limited (Chi-Med): Product Portfolio

Table 46 Hutchison China MediTech Limited (Chi-Med): Key Developments

Table 47 Progenics Pharmaceuticals: Overview

Table 48 Progenics Pharmaceuticals: Product Portfolio

Table 49 Progenics Pharmaceuticals: Key Developments

Table 50 Ipsen Pharma: Overview

Table 51 Ipsen Pharma: Product Portfolio

Table 52 Ipsen Pharma: Key Developments

Table 53 Teva Pharmaceutical Industries Ltd.: Overview

Table 54 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 55 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 56 Helsinn Group: Overview

Table 57 Helsinn Group: Product Portfolio

Table 58 Helsinn Group: Key Developments

Table 59 Omega Laboratories Ltd.: Overview

Table 60 Omega Laboratories Ltd.: Product Portfolio

Table 61 Omega Laboratories Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 2 Global Carcinoid Syndrome Diarrhea Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 3 Global Carcinoid Syndrome Diarrhea Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 4 Global Carcinoid Syndrome Diarrhea Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 5 Global Carcinoid Syndrome Diarrhea Treatment Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Carcinoid Syndrome Diarrhea Treatment Market Y-o-Y Growth, By Therapy Type, 2022-2030 (%)

Figure 7 Chemotherapy Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 8 Somatostatin Analog (SSA) Therapy Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 9 Others Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 10 Global Carcinoid Syndrome Diarrhea Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 11 Retail Pharmacy Distribution Channel in Global Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 12 Hospital Pharmacy Distribution Channel in Global Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 13 Online Pharmacy Distribution Channel in Global Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 14 Global Carcinoid Syndrome Diarrhea Treatment Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 15 Hospitals End User in Global Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 16 Cancer Research Center End User in Global Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 17 Ambulatory Surgery Centers End User in Global Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 18 Global Carcinoid Syndrome Diarrhea Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 19 North America Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 20 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 21 Europe Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 22 South America Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 23 Middle East and Africa Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 24 North America Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 25 North America Carcinoid Syndrome Diarrhea Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 26 North America Carcinoid Syndrome Diarrhea Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 27 North America Carcinoid Syndrome Diarrhea Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 28 North America Carcinoid Syndrome Diarrhea Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 29 South America Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 30 South America Carcinoid Syndrome Diarrhea Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 31 South America Carcinoid Syndrome Diarrhea Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 32 South America Carcinoid Syndrome Diarrhea Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 33 South America Carcinoid Syndrome Diarrhea Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 34 Europe Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 35 Europe Carcinoid Syndrome Diarrhea Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 36 Europe Carcinoid Syndrome Diarrhea Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 37 Europe Carcinoid Syndrome Diarrhea Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 38 Europe Carcinoid Syndrome Diarrhea Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 39 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 40 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 41 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 42 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 43 Asia-Pacific Carcinoid Syndrome Diarrhea Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 44 Middle East & Africa Carcinoid Syndrome Diarrhea Treatment Market Value, 2022-2031 (US$ Million)

Figure 45 Middle East & Africa Carcinoid Syndrome Diarrhea Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 46 Middle East & Africa Carcinoid Syndrome Diarrhea Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 47 Middle East & Africa Carcinoid Syndrome Diarrhea Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 48 Novartis AG: Financials

Figure 49 Lexicon Pharmaceuticals: Financials

Figure 50 Ipsen Biopharmaceuticals: Financials

Figure 51 Pfizer Inc.: Financials

Figure 52 Hutchison China MediTech Limited (Chi-Med): Financials

Figure 53 Progenics Pharmaceuticals: Financials

Figure 54 Ipsen Pharma: Financials

Figure 55 Teva Pharmaceutical Industries Ltd.: Financials

Figure 56 Helsinn Group: Financials

Figure 57 Omega Laboratories Ltd.: Financials

세계 카르시노이드 증후군 설사 치료 시장 – 2023-2030

Global Carcinoid Syndrome Diarrhea Treatment Market - 2023-2030